Lung Cancer Panel 8 (EGFR, BRAF, ALK, ROS, MET, PDL1) Comprehensive Genetic Testing
Understanding Lung Cancer Genetic Testing
Lung cancer remains one of the most prevalent and challenging cancers worldwide, but recent advances in molecular diagnostics have revolutionized treatment approaches. The Lung Cancer Panel 8 represents a cutting-edge genetic testing solution that analyzes six critical biomarkers: EGFR, BRAF, ALK, ROS, MET, and PDL1. This comprehensive panel provides oncologists with essential information to develop personalized treatment strategies based on the specific genetic profile of each patient’s cancer.
Traditional cancer treatments often follow a one-size-fits-all approach, but modern oncology recognizes that lung cancer is not a single disease but rather a collection of distinct molecular subtypes. The Lung Cancer Panel 8 enables precision medicine by identifying the unique genetic drivers of an individual’s cancer, allowing for targeted therapies that specifically address the molecular abnormalities driving tumor growth.
What the Test Measures and Detects
The Lung Cancer Panel 8 utilizes advanced molecular techniques including FISH, Sanger Sequencing, and IHC to detect specific genetic alterations:
Key Biomarkers Analyzed:
- EGFR Mutations: Epidermal Growth Factor Receptor mutations that respond to EGFR tyrosine kinase inhibitors
- BRAF Mutations: Genetic alterations in the BRAF gene that can be targeted with specific inhibitors
- ALK Rearrangements: Anaplastic Lymphoma Kinase gene fusions that predict response to ALK inhibitors
- ROS1 Rearrangements: ROS1 gene fusions that indicate sensitivity to targeted therapies
- MET Amplifications: MET gene amplifications that may respond to MET inhibitors
- PDL1 Expression: Programmed Death-Ligand 1 protein levels that predict response to immunotherapy
Who Should Consider This Test
The Lung Cancer Panel 8 is recommended for individuals with:
Clinical Indications:
- Newly diagnosed non-small cell lung cancer (NSCLC) patients
- Patients with advanced or metastatic lung cancer
- Individuals who have failed initial chemotherapy treatments
- Patients with recurrent lung cancer
- Those seeking personalized treatment options
- Individuals with family history of lung cancer
- Patients experiencing persistent respiratory symptoms with suspicious findings
Symptoms That May Warrant Testing:
- Persistent cough that doesn’t resolve
- Chest pain that worsens with deep breathing or coughing
- Shortness of breath or wheezing
- Coughing up blood or rust-colored phlegm
- Unexplained weight loss and fatigue
- Recurrent respiratory infections
- Hoarseness that persists
Benefits of Taking the Lung Cancer Panel 8 Test
Personalized Treatment Planning
The primary benefit of this comprehensive genetic panel is the ability to match patients with targeted therapies that specifically address their cancer’s genetic profile. This precision medicine approach can lead to:
- Improved treatment response rates
- Reduced side effects compared to traditional chemotherapy
- Longer progression-free survival
- Better quality of life during treatment
- More informed treatment decisions
Comprehensive Molecular Profiling
Unlike single-gene tests, the Lung Cancer Panel 8 provides a complete picture of multiple relevant biomarkers simultaneously, saving time and tissue samples while ensuring no critical mutations are missed.
Understanding Your Test Results
Positive Results
A positive result for any of the biomarkers indicates the presence of a specific genetic alteration that may respond to targeted therapy. Your oncologist will discuss:
- Available targeted treatment options
- Expected response rates
- Potential side effects
- Monitoring requirements during treatment
Negative Results
If no targetable mutations are detected, your healthcare team will discuss alternative treatment strategies, including conventional chemotherapy, radiation, or participation in clinical trials for novel therapies.
Interpretation Guidance
All results should be interpreted by a qualified oncologist or genetic counselor who can explain the clinical significance of the findings and how they impact your treatment options. The presence of multiple mutations may indicate more complex treatment approaches or combination therapies.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | Lung Cancer Panel 8 (EGFR, BRAF, ALK, ROS, MET, PDL1) |
| Regular Price | $1500 USD |
| Discount Price | $1126 USD |
| Turnaround Time | 5-7 days |
| Sample Type | Tumor tissue (Paraffin embedded tissue blocks) |
| Testing Methods | FISH, Sanger Sequencing, IHC |
| Prescription Required | Doctor’s prescription required (not applicable for surgery, pregnancy, or travel abroad cases) |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified laboratories ensures consistent, high-quality testing standards nationwide.
Take Control of Your Lung Cancer Treatment
Don’t leave your treatment decisions to chance. The Lung Cancer Panel 8 provides the critical genetic information needed to pursue the most effective, personalized treatment strategy for your specific cancer type. With our discounted price of $1126 USD, this comprehensive testing is more accessible than ever.
Ready to get started? Book your Lung Cancer Panel 8 test today by calling our dedicated healthcare team at +1(267) 388-9828 or schedule your appointment online. Our genetic counselors are available to answer your questions and guide you through the testing process.
Take the first step toward personalized lung cancer care with the comprehensive genetic insights provided by the Lung Cancer Panel 8. Your journey to targeted, effective treatment begins with understanding your cancer at the molecular level.
